BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

525 related articles for article (PubMed ID: 26362172)

  • 1. Cost-effectiveness of high-dose versus standard-dose inactivated influenza vaccine in adults aged 65 years and older: an economic evaluation of data from a randomised controlled trial.
    Chit A; Becker DL; DiazGranados CA; Maschio M; Yau E; Drummond M
    Lancet Infect Dis; 2015 Dec; 15(12):1459-66. PubMed ID: 26362172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose inactivated influenza vaccine is associated with cost savings and better outcomes compared to standard-dose inactivated influenza vaccine in Canadian seniors.
    Becker DL; Chit A; DiazGranados CA; Maschio M; Yau E; Drummond M
    Hum Vaccin Immunother; 2016 Dec; 12(12):3036-3042. PubMed ID: 27669017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expected cost effectiveness of high-dose trivalent influenza vaccine in US seniors.
    Chit A; Roiz J; Briquet B; Greenberg DP
    Vaccine; 2015 Jan; 33(5):734-41. PubMed ID: 25444791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States.
    Luce BR; Nichol KL; Belshe RB; Frick KD; Li SX; Boscoe A; Rousculp MD; Mahadevia PJ
    Vaccine; 2008 Jun; 26(23):2841-8. PubMed ID: 18462851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis.
    Izurieta HS; Thadani N; Shay DK; Lu Y; Maurer A; Foppa IM; Franks R; Pratt D; Forshee RA; MaCurdy T; Worrall C; Howery AE; Kelman J
    Lancet Infect Dis; 2015 Mar; 15(3):293-300. PubMed ID: 25672568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of high-dose versus standard-dose influenza vaccination on numbers of US nursing home residents admitted to hospital: a cluster-randomised trial.
    Gravenstein S; Davidson HE; Taljaard M; Ogarek J; Gozalo P; Han L; Mor V
    Lancet Respir Med; 2017 Sep; 5(9):738-746. PubMed ID: 28736045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of a recommendation of universal mass vaccination for seasonal influenza in the United States.
    Clements KM; Chancellor J; Nichol K; DeLong K; Thompson D
    Value Health; 2011; 14(6):800-11. PubMed ID: 21914499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy.
    Mennini FS; Bini C; Marcellusi A; Rinaldi A; Franco E
    Hum Vaccin Immunother; 2018; 14(8):1867-1873. PubMed ID: 29708843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Assessment of the Expected Cost-Effectiveness of Quadrivalent Influenza Vaccines in Ontario, Canada Using a Static Model.
    Chit A; Roiz J; Aballea S
    PLoS One; 2015; 10(7):e0133606. PubMed ID: 26222538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of quadrivalent versus trivalent influenza vaccine in Taiwan: A lifetime multi-cohort model.
    Yang MC; Tan EC; Su JJ
    Hum Vaccin Immunother; 2017 Jan; 13(1):81-89. PubMed ID: 27624648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of Quadrivalent versus Trivalent Influenza Vaccine in the United States.
    de Boer PT; Crépey P; Pitman RJ; Macabeo B; Chit A; Postma MJ
    Value Health; 2016 Dec; 19(8):964-975. PubMed ID: 27987647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong.
    You JH; Ming WK; Chan PK
    BMC Infect Dis; 2014 Nov; 14():618. PubMed ID: 25420713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of influenza and pneumococcal vaccination for Hong Kong elderly in long-term care facilities.
    You JH; Wong WC; Ip M; Lee NL; Ho SC
    J Epidemiol Community Health; 2009 Nov; 63(11):906-11. PubMed ID: 19608558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea.
    Kim YK; Song JY; Jang H; Kim TH; Koo H; Varghese L; Han E
    Pharmacoeconomics; 2018 Dec; 36(12):1475-1490. PubMed ID: 30251078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of quadrivalent influenza vaccine in Hong Kong - A decision analysis.
    You JH; Ming WK; Chan PK
    Hum Vaccin Immunother; 2015; 11(3):564-71. PubMed ID: 25714506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model.
    Aballéa S; Chancellor J; Martin M; Wutzler P; Carrat F; Gasparini R; Toniolo-Neto J; Drummond M; Weinstein M
    Value Health; 2007; 10(2):98-116. PubMed ID: 17391419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of quadrivalent influenza vaccination in at-risk adults and the elderly: an updated analysis in the U.K.
    Meier G; Gregg M; Poulsen Nautrup B
    J Med Econ; 2015; 18(9):746-61. PubMed ID: 25903831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, randomised phase 4 trial.
    Tapia MD; Sow SO; Tamboura B; Tégueté I; Pasetti MF; Kodio M; Onwuchekwa U; Tennant SM; Blackwelder WC; Coulibaly F; Traoré A; Keita AM; Haidara FC; Diallo F; Doumbia M; Sanogo D; DeMatt E; Schluterman NH; Buchwald A; Kotloff KL; Chen WH; Orenstein EW; Orenstein LAV; Villanueva J; Bresee J; Treanor J; Levine MM
    Lancet Infect Dis; 2016 Sep; 16(9):1026-1035. PubMed ID: 27261067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of different seasonal influenza vaccines in the elderly Italian population.
    Capri S; Barbieri M; de Waure C; Boccalini S; Panatto D
    Hum Vaccin Immunother; 2018 Jun; 14(6):1331-1341. PubMed ID: 29425079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.